铂耐药卵巢癌的免疫治疗
本文综述免疫治疗在铂耐药卵巢癌中的应用证据。卵巢癌复发率高,铂耐药患者预后差且缺乏有效治疗手段,目前以单药化疗为主;已有证据尚不支持常规采用免疫治疗,需进一步探索策略。
要点
- 铂耐药卵巢癌目前仍以单药化疗为主要治疗手段
- 尚无成熟证据支持卵巢癌常规应用免疫治疗
- 免疫治疗在铂耐药卵巢癌中的策略仍需进一步探索
核心结论
- 尚无成熟证据支持在卵巢癌患者中常规采用免疫治疗,仍需探索进一步策略。
研究设计与样本
- 本文为综述,汇总免疫治疗用于铂耐药卵巢癌的现有证据;原文未报告检索范围与样本量。
主要发现
- 卵巢癌发病率与死亡率之比高,多数患者初治后达完全缓解,但约65-80%在5年内复发。
- 无铂间期是主要预后因素之一,含铂化疗结束后6个月内复发者预后差。
- 铂耐药卵巢癌的主要治疗为单药化疗,其他治疗模式在此背景下结果令人沮丧。
- 越来越多证据提示免疫治疗可改善多种实体瘤(包括黑色素瘤、非小细胞肺癌及子宫恶性肿瘤)患者的结局。
临床怎么用
- 铂耐药卵巢癌现阶段不应常规采用免疫治疗,应以单药化疗为主要治疗。
- 免疫治疗的应用应限于研究或探索性策略,不宜作为常规临床选择。
局限性
- 原文为综述且明确指出尚无成熟证据,未报告具体研究设计、样本量与疗效数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ovarian cancer is characterized by a high mortality on incidence ratio. Although the majority of patients achieve complete response after primary treatment, approximately 65-80% of patients recur with the first 5 years. Platinum-free interval is one of the main prognostic factors. Patients recurring with 6 months within the end of platinum-based chemotherapy are characterized by poor prognosis. To date no effective treatment modality are identified for those patients. The mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment modalities have tested in this setting with discouraging results. Growing evidence suggested that immunotherapy would improve outcomes of patients with various types of solid tumors including melanoma, non-small cell lung cancer as well as uterine malignancies. Here, we reviewed current evidence on the adoption of immunotherapy in platinum-resistant ovarian cancer. To date no mature evidence supports the routine adoption of immunotherapy in ovarian cancer patients. Further strategies have to be explored.
引用
- Bogani G, Lopez S, Mantiero M, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020. PMID: 32518015. doi:10.1016/j.ygyno.2020.05.681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。